Effect and Safety of Fosaprepitant Dimeglumine for the Management of Chemotherapy-Induced Nausea and Vomiting: an Observational Registry Study

Fosaprepitant Dimeglumine for the Management of Chemotherapy-Induced Nausea and Vomiting: an Observational Registry Study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039884

Enrollment

Unknown

Registered

2020-11-13

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who prescribed Fosaprepitant Dimeglumine for injection to prevent chemotherapy-induced nausea and vomiting; 2.Patients who volunteered to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Hypersensitive to any component of this product; 2.Patients taking pimozide, terfenadine, astemizole and cisapride.

Design outcomes

Primary

Measure	Time frame
CR;	—

Secondary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactLi Yan

Shandong Provincial Qianfoshan Hospital

liyan16766@163.com+86 13791120807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026